Comtan (entacapone), a new COMT inhibitor for advanced Parkinson's disease

Novartis is now marketing Comtan (entacapone), a new COMT inhibitor for advanced Parkinson's disease.

It's used to enhance the effectiveness of levodopa/carbidopa or levodopa/benserazide.

Comtan decreases the metabolism of levodopa...leading to more sustained levels. This smooths out the response to levodopa and reduces "wearing off" periods.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote